HOUSTON, May 21, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications, today announced that its
President and Chief Executive Officer, Peter L. Hoang, will present at and participate
in two upcoming investor conferences:
Sachs Associates 5th Annual Immuno-Oncology
BD&L and Investment Forum – Latest Advances in Cell & Gene
Therapies Panel
Date: Friday, May 31, 2019
Location: Waldorf Astoria Chicago Hotel
Time: 12:10pm CDT: Company
Presentation
2:30pm
CDT: Panel – Latest Advances in Cell & Gene Therapies
Jefferies 2019 Global Healthcare Conference
Date:
Friday, June 7, 2019
Location: New York, NY
Time: 11:00am EDT
A live webcast of both event presentations will be available in
the investors section of the company's website at
www.markertherapeutics.com and will be available for replay
following the events.
About Marker Therapeutics,
Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
This population of T cells is designed to attack multiple tumor
targets following infusion into patients and to activate the
patient's immune system to produce broad spectrum anti-tumor
activity. Because Marker does not genetically engineer its T cells
therapies, we believe that our product candidates will be easier
and less expensive to manufacture, with reduced toxicities,
compared to current engineered CAR-T and TCR-based approaches, and
may provide patients with meaningful clinical benefit. As a result,
Marker believes its portfolio of T cell therapies has a compelling
therapeutic product profile, as compared to current gene-modified
CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase 2 clinical
trials.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us
on Facebook.
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell
therapies; our TPIV200 and TPIV100/110 programs; the effectiveness
of these programs or the possible range of application and
potential curative effects and safety in the treatment of diseases;
and, the timing and success of our clinical trials, as well as
clinical trials conducted by our collaborators. Forward-looking
statements are by their nature subject to risks, uncertainties and
other factors which could cause actual results to differ materially
from those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-two-upcoming-investor-conferences-300853521.html
SOURCE Marker Therapeutics, Inc.